Aptevo Therapeutics Files 8-K

TL;DR

APVO filed a routine 8-K, confirming HQ and Nasdaq listing.

AI Summary

Aptevo Therapeutics Inc. filed an 8-K on February 11, 2025, reporting its status as a publicly traded company. The filing confirms its principal executive offices are located at 2401 4th Avenue, Suite 1050, Seattle, Washington, 98121, and its common stock trades on The Nasdaq Stock Market LLC under the symbol APVO.

Why It Matters

This 8-K filing serves as a standard corporate disclosure, confirming basic information about Aptevo Therapeutics Inc. and its stock listing.

Risk Assessment

Risk Level: low — This filing is a routine corporate disclosure and does not contain new material information that would inherently increase risk.

Key Players & Entities

• Aptevo Therapeutics Inc. (company) — Registrant
• February 11, 2025 (date) — Date of earliest event reported
• 2401 4th Avenue, Suite 1050, Seattle, Washington, 98121 (location) — Address of Principal Executive Offices
• APVO (ticker) — Trading Symbol for Common Stock
• The Nasdaq Stock Market LLC (company) — Exchange where Common Stock is registered

FAQ

Key Financial Figures

• $0.001 — nge on which registered Common Stock, $0.001 par value APVO The Nasdaq Stock Mar

Filing Documents

• apvo-20250211.htm (8-K) — 42KB
• apvo-ex99_1.htm (EX-99.1) — 37KB
• apvo-ex99_1s1.jpg (GRAPHIC) — 172KB
• apvo-ex99_1s2.jpg (GRAPHIC) — 1033KB
• apvo-ex99_1s3.jpg (GRAPHIC) — 640KB
• apvo-ex99_1s4.jpg (GRAPHIC) — 589KB
• apvo-ex99_1s5.jpg (GRAPHIC) — 456KB
• apvo-ex99_1s6.jpg (GRAPHIC) — 373KB
• apvo-ex99_1s7.jpg (GRAPHIC) — 319KB
• apvo-ex99_1s8.jpg (GRAPHIC) — 714KB
• apvo-ex99_1s9.jpg (GRAPHIC) — 707KB
• apvo-ex99_1s10.jpg (GRAPHIC) — 567KB
• apvo-ex99_1s11.jpg (GRAPHIC) — 519KB
• apvo-ex99_1s12.jpg (GRAPHIC) — 327KB
• apvo-ex99_1s13.jpg (GRAPHIC) — 751KB
• apvo-ex99_1s14.jpg (GRAPHIC) — 170KB
• apvo-ex99_1s15.jpg (GRAPHIC) — 539KB
• apvo-ex99_1s16.jpg (GRAPHIC) — 540KB
• apvo-ex99_1s17.jpg (GRAPHIC) — 159KB
• apvo-ex99_1s18.jpg (GRAPHIC) — 469KB
• apvo-ex99_1s19.jpg (GRAPHIC) — 640KB
• apvo-ex99_1s20.jpg (GRAPHIC) — 156KB
• apvo-ex99_1s21.jpg (GRAPHIC) — 622KB
• apvo-ex99_1s22.jpg (GRAPHIC) — 564KB
• apvo-ex99_1s23.jpg (GRAPHIC) — 355KB
• apvo-ex99_1s24.jpg (GRAPHIC) — 593KB
• apvo-ex99_1s25.jpg (GRAPHIC) — 528KB
• apvo-ex99_1s26.jpg (GRAPHIC) — 652KB
• apvo-ex99_1s27.jpg (GRAPHIC) — 758KB
• apvo-ex99_1s28.jpg (GRAPHIC) — 505KB
• apvo-ex99_1s29.jpg (GRAPHIC) — 454KB
• apvo-ex99_1s30.jpg (GRAPHIC) — 256KB
• 0000950170-25-017473.txt ( ) — 21033KB
• apvo-20250211.xsd (EX-101.SCH) — 25KB
• apvo-20250211_htm.xml (XML) — 5KB

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On February 11, 2025, Aptevo Therapeutics Inc. ("Aptevo" or the "Company") made available its investor presentation which details the Company's current drug pipeline, including clinical product candidates mipletamig and ALG.APV-527 and preclinical candidates APVO711, APVO603 and APVO442. A copy of the presentation is attached hereto as Exhibit 99.1 and is incorporated by reference herein.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Investor Presentation 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. APTEVO THERAPEUTICS INC. Date: February 11, 2025 By: /s/ Marvin L. White Marvin L. White President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR